VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · IEX Real-Time Price · USD
2.130
-0.020 (-0.93%)
At close: Jul 19, 2024, 4:30 PM
2.150
+0.020 (0.94%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
VYNE Therapeutics Revenue
VYNE Therapeutics had revenue of $423.00K in the twelve months ending March 31, 2024, with 6.28% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $98.00K. In the year 2023, VYNE Therapeutics had annual revenue of $424.00K.
Revenue (ttm)
$423.00K
Revenue Growth
+6.28%
P/S Ratio
73.16
Revenue / Employee
$42,300
Employees
10
Market Cap
30.95M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 424.00K | -53.00K | -11.11% |
Dec 31, 2022 | 477.00K | -454.00K | -48.76% |
Dec 31, 2021 | 931.00K | -20.06M | -95.57% |
Dec 31, 2020 | 20.99M | 20.55M | 4,638.83% |
Dec 31, 2019 | 443.00K | -3.15M | -87.68% |
Dec 31, 2018 | 3.60M | -987.00K | -21.54% |
Dec 31, 2017 | 4.58M | 3.91M | 579.82% |
Dec 31, 2016 | 674.00K | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cutera | 196.64M |
CareCloud | 113.02M |
IRIDEX | 49.92M |
Equillium | 37.89M |
Longeveron | 978.00K |
VYNE News
- 25 days ago - VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewsWire
- 5 weeks ago - VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202 - GlobeNewsWire
- 2 months ago - VYNE Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 2 months ago - VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting - GlobeNewsWire
- 4 months ago - VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire
- 5 months ago - VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium - GlobeNewsWire